|
Real-time Estimate
Cboe BZX
12:44:10 15/07/2026 am IST
|
5-day change
|
1st Jan Change
|
|
55.68 USD
|
-0.64%
|
 |
-2.54%
|
+26.92%
|
|
22/06 |
Exelixis Provides Update on the Phase 3 Stellar-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
|
CI
| |
30/05 |
Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026
|
CI
| |
22/05 |
Exelixis, Inc. Announces Presentations of Cabometyx and Zanzalintinib At 2026 2026 Annual Meeting
|
CI
| |
06/05 |
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.58B
|
MT
| |
06/05 |
Exelixis Q1 Non-GAAP Earnings, Revenue Rise
|
MT
| |
06/05 |
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M
|
MT
| |
06/05 |
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76
|
MT
| |
06/05 |
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76
|
MT
| |
06/05 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
|
CI
| |
06/05 |
Exelixis, Inc. announces an Equity Buyback for $750 million worth of its shares.
|
CI
| |
06/05 |
Exelixis, Inc. Maintains Earnings Guidance for Fiscal Year 2026
|
CI
| |
06/05 |
Exelixis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
01/05 |
Exelixis, Inc. authorizes a Buyback Plan.
|
CI
| |
11/02 |
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.62B
|
MT
| |
11/02 |
Exelixis Q4 Non-GAAP Earnings, Revenue Rise
|
MT
| |
11/02 |
Earnings Flash (EXEL) Exelixis, Inc. Reports Q4 Revenue $598.7M, vs. FactSet Est of $596.5M
|
MT
| |
11/02 |
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
|
CI
| |
11/02 |
Earnings Flash (EXEL) Exelixis, Inc. Posts Q4 Adjusted EPS $0.94 per Share, vs. FactSet Est of $0.83
|
MT
| |
02/02 |
Exelixis, Inc. Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
|
CI
| |
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.
|
CI
| |
13/01 |
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on February 20, 2025.
|
CI
| |
12/01 |
Exelixis Provides Fiscal 2026 Revenue Guidance
|
MT
| |
12/01 |
Exelixis says fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion
|
RE
| |
12/01 |
Exelixis, Inc. Announces Preliminary Financial Results for the Year 2025 and Provides Financial Guidance for the Year 2026
|
CI
| |
31/12 |
Exelixis, Inc.'s Equity Buyback announced on February 20, 2025, has closed with 12,207,187 shares, representing 4.48% for $500 million.
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
Choose MarketScreener 
